Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

References

1. Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: A Bayesian network meta-analysis of randomized controlled trials. Lupus 2015 Jul 9. 0961203315595131 [Epub ahead of print–abstract]
2. Kuznar W. Tacrolimus comes out tops for lupus nephritis. Medpage Today. 2015 Jul 24.
3. U.S. Food and Drug Administration. Nonproprietary naming of biological products; draft guidance for industry; availability. Federal Register. 2015 Aug 28.
4. American College of Rheumatology. Press release: American College of Rheumatology applauds FDA draft guidance requiring distinct naming for biosimilars. 2015 Aug 28.